Kim N Chi, MD
British Columbia Cancer Agency · British Columbia Cancer Agency - Vancouver Centre · British Columbia Cancer Agency, Univeristy of British Columbia
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Kim N Chi, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 09:57 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT04015622 · PROstate Cancer TReatment Optimization Via Analysis of Circulating Tumour DNABritish Columbia Cancer Agency · active not recruiting · Metastatic Castration-Resistant Prostate Cancer (mCRPC) · study chair
- Ph1/Ph2NCT02606123 · Safety and Anti-Tumor Study of Oral EPI-506 for Patients With Metastatic Castration-Resistant Prostate CancerESSA Pharmaceuticals · terminated · Prostatic Neoplasms, Genital Neoplasms, Male, Genital Diseases, Male · principal investigator
- Ph2NCT02254785 · Cabazitaxel vs Abiraterone or Enzalutamide in Patients With Poor Prognosis Metastatic Castration-resistant Prostate CancerBritish Columbia Cancer Agency · unknown · Metastatic Castration-Resistant Prostatic Cancer · principal investigator
- Ph2NCT02125357 · Sequencing Abiraterone and Enzalutamide in mCRPCBritish Columbia Cancer Agency · completed · Metastatic Castration-Resistant Prostate Cancer · study chair
- Ph2NCT01630967 · Efficacy Study of Switching to a Lutenizing Hormone-releasing Hormone (LHRH) Antagonist From a LHRH Agonist to Treat Progressive Castrate Resistant Prostate Cancer (CRPC)British Columbia Cancer Agency · withdrawn · Prostate Neoplasm · principal investigator
- Ph2NCT01120470 · OGX-427 in Castration Resistant Prostate Cancer PatientsBritish Columbia Cancer Agency · completed · Castration Resistant Prostate Cancer · study chair
- Ph2NCT01075308 · SB939 in Treating Patients With Recurrent or Metastatic Prostate CancerNCIC Clinical Trials Group · completed · Prostate Cancer · study chair
- Ph3NCT00651326 · Androgen Suppression and Radiation With/Out Docetaxel in High-Risk Localized Prostate CancerNCIC Clinical Trials Group · terminated · Prostate Cancer · study chair
- Ph1NCT00471432 · OGX-011 and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Solid TumorsNCIC Clinical Trials Group · completed · Bladder Cancer, Breast Cancer, Kidney Cancer · study chair
- Ph2NCT00430235 · A Study of BAY 43-9006 in Combination With Bicalutamide in Patients With Chemo-Naïve Hormone Refractory Prostate CancerBritish Columbia Cancer Agency · completed · Adenocarcinoma of the Prostate · study chair
- Ph2NCT00258388 · Docetaxel and Prednisone With/Out OGX-011 in Recurrent or Metastatic Prostate Cancer That Did Not Respond to Previous Hormone TherapyNCIC Clinical Trials Group · completed · Prostate Cancer · study chair
- Ph2NCT00093457 · Sorafenib in Treating Patients With Metastatic or Recurrent Prostate CancerNCIC Clinical Trials Group · completed · Prostate Cancer · study chair
- Ph1NCT00054106 · Hormone Therapy and OGX-011 Before Radical Prostatectomy in Treating Patients With Prostate CancerNCIC Clinical Trials Group · completed · Prostate Cancer · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 09:57 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.